The modern view on optimal therapy of HPV-associated pathology of cervix at the vaginal dysbiosis background




HPV-associated cervical pathology, vaginal dysbiosis, lactobacilli, Lactoginal


Human papillomavirus (HPV) is a proven cause of precancer and cervical cancer. Violation of the vaginal microbiota in women with HPV-associated cervical pathology may contribute to the development of carcinogenesis. Deficiency of lactobacillus contributes to the growth and development of opportunistic microorganisms, reducing the synthesis of bactericidal and antifungal substances.

The study of the clinical efficacy of the vaginal Lactoginal® (strain Lactobacillus rhamnosus LCR35), in the complex treatment of HPV-associated cervical pathology at the vaginal dysbiosis background’s.

The results of the study showed a significant decrease in cases of vaginal dysbiosis, an increase in the number of lactobacilli in the vaginal secretion, a decrease in the microbial associations of relative pathogenic flora, an improvement in local immunity and complete elimination of HPV with the addition of the Lactoginal® to the basic therapy. The results obtained allow us to recommend the Lactoginal® for treatment of precancerous diseases of the cervix.

Author Biographies

О. А. Таран, Vinnytsya National Pirogov Memorial Medical University

MD, associate professor of the Department of Obstetrics and Gynecology No. 1

О. В. Булавенко, Vinnytsya National Pirogov Memorial Medical University

MD, professor, head of the Department of Obstetrics and Gynecology No. 2

Д. Г. Коньков, Vinnytsya National Pirogov Memorial Medical University

MD, professor of the Department of Obstetrics and Gynecology No. 1

Т. В. Лобастова, Vinnytsya National Pirogov Memorial Medical University

PhD, assistant of the Department of Obstetrics and Gynecology No. 1


  1. Brotman, R.M., et al. “Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection.” J Infect Dis 210 (2014): 1723–33.
  2. De Kok, I.M., van Rosmalen, J., Dillner, J., et al. “Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.” Br Med J 344 (2012): 670.
  3. Einstein, M.H., Schiller, J.T., Viscidi, R.P., et al. “Clinician’s guide to human papillomavirus immunology: knowns and unknowns.” Lancet Infectious Diseases 9.6 (2009): 347–56.
  4. Сhauhan, S.C., et al. “Epidemiology of human papillomavirus (HPV) in cervical mucosa.” Meth in Mol Biol 471 (2009): 439–56.
  5. Franceschi, S., Plummer, M., Clifford, G. “Differences in the risk of cervical cancer and human papillomavirus infection by education level.” British Journal of Cancer 101.5 (2009): 865–70.
  6. Gao, W., Weng, J., Gao, Y., Chen, X. “Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study.” BMC Infect Dis 13 (2013): 271.
  7. Gillet, E., et al. “Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis.” BMC Infect Dis 11 (2011): 10.
  8. Fitzmaurice, C., Allen, C., Barber, R.M., et al.; Global burden of disease cancer collaboration. “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.” JAMA Oncol 3 (2017): 524–48.
  9. Grimm, C., Polterauer, S., Natter, C. “Treatment of cervical intraepithelial neoplasia.” Obstet Gynecol 120.1 (2012): 152–9.
  10. Guo, Y.L., You, K., Qiao, J., et al. “Bacterial vaginosis is conducive to the persistence of HPV infection.” Int J STD AIDS 23 (2012): 581–4.
  11. Lee, J.E., et al. “Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort.” PLoS One 8 (2013): e63514.
  12. Maucort-Boulch, D., Plummer, M., Castle, P.E., Demuth, F. “Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology.” Int J Cancer 126.93 (2010): 684–91.
  13. Murphy, J., Kennedy, E.B., Dunn, S. “Cervical screening: a guideline for clinical practice in Ontario.” J Obstet Gynaecol Can 34.5 (2012): 453–8.
  14. Siegel, R. L., et al. “Cancer statistics for Hispanics/Latinos.” CA Cancer J Clin 65 (2015): 457–80.
  15. Viens, L.J., et al. “Human papillomavirus-associated cancers - United States, 2008-2012.” MMWR Morb Mortal Wkly Rep 65 (2016): 661–6.
  16. Watts, D.H., et al. “Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infectionin HIV-1-infected andhigh-risk HIV-1-uninfected women.” J Infect Dis 191 (2005): 1129–39.
  17. Mitra, A., MacIntyre, D.A., Marchesi, J.R., et al. “The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?” Microbiome 4 (2016): 58.
  18. Savicheva, A., Rybina, E. “In vitro study of the growth, reproduction, antibiotic resistance and competitive relationships of a Lactobacillus casei rhamnosus strain.” Obstetrics and Gynecology 7 (2014): 79–83.
  19. Atassi, F., Brassart, D., Grob, P., et al. “Lactobacillus strains isolated from the vaginal microbiota of healthy women inhibit Prevotella bivia and Gardnerella vaginalis in coculture and cell culture.” FEMS Immunol Med Microbiol 48.3 (2006): 424–32.
  20. Dover, S.E., et al. “Safety study of an antimicrobial peptide lactocin 160, produced by the vaginal Lactobacillus rhamnosus.” Infect Dis Obstet Gynecol (2007). Article ID 78248. DOI: 10.1155/2007/78248



How to Cite

Таран, О. А., Булавенко, О. В., Коньков, Д. Г., & Лобастова, Т. В. (2018). The modern view on optimal therapy of HPV-associated pathology of cervix at the vaginal dysbiosis background. REPRODUCTIVE ENDOCRINOLOGY, (44), 16–20.